Erin Lavelle's Insider Trades & SAST Disclosures
Erin Lavelle's most recent trade in Neoleukin Therapeutics Inc was a trade of 25,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 8, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Erin Lavelle.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neoleukin Therapeutics Inc | Erin M. Lavelle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Climb Bio Inc. | Erin M. Lavelle | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2022 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Neoleukin Therapeutics Inc | Erin M. Lavelle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Climb Bio Inc. | Erin M. Lavelle | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Neoleukin Therapeutics Inc | Erin M. Lavelle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Neoleukin Therapeutics Inc | Erin Lavelle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges